soon, when CUSA goes on backorder then we can focus all out attention to the single worst idea integra has ever had. Replacing Kranios with a clearly inferior product in an over saturated market, with zero leverage against even the worst of the competition. we will surely take a bath on this, and our product manager ( have they seen the inside of an OR), Pharma leaders ( ditto) and with the inability to cross sell, having, I believe every product we carry on back order, recall , limited ship, should make for a great Q3. nerver fear. soon we may have a second attempt at trying to replace out one shining product. sigh